PubChem Substance Record for SID 319360420, 386264-39-7, Source: ToxPlanet
Following the application of inclusion criteria, such as maintaining the prescribed dosage for a minimum of 180 days, 169 participants were included in the final analysis
6.3 Promise of multi-targeted combination therapies in RA treatment The core of multi-target combination therapy lies in remodeling the metabolic-immune homeostasis in the pathological microenvironment of RA through the synergistic metabolic intervention and immunomodulation
Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al
406 In the final clinical trial, the SURMOUNT-3 trial, the effect of tirzepatide on weight reduction after successful intensive lifestyle intervention was tested